# Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

> **NCT03930641** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DRUG:** RTH258

## Key facts

- **NCT ID:** NCT03930641
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-23
- **Primary completion:** 2019-07-02
- **Final completion:** 2019-07-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930641, "Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03930641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*